Flow Cytometry Market by Technology (Cell-based, Bead-based), Product & Service (Analyzer, Sorter, Consumables, Software), Application ((Research - Immunology, Stem cell), (Clinical - Hematology)), End User (Biotech, Hospitals) & Region - Global Forecast to 2027
Updated on : March 31, 2023
The global flow cytometry market in terms of revenue was estimated to be worth $4.7 billion in 2022 and is poised to grow at a CAGR of 8.1% from 2022 to 2027.
The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The growth of the global market is largely driven by the rising prevalence of HIV/AIDS and cancer, the growing adoption of flow cytometry techniques in research activities, increasing public-private initiatives in immunology and immuno-oncology research, and the rising technological advancements in flow cytometry software.
To know about the assumptions considered for the study, Request for Free Sample Report
Flow Cytometry Market Dynamics
Drivers: Technological advancements in flow cytometry instruments is projecting the market growth
Key players operating in the global market are increasingly focused on developing and commercializing technologically advanced flow cytometry products that offer streamlined workflows, ease of operability, and improved turnaround times. Such innovative products are expected to show significant demand growth during the forecast period, especially in mature markets where the adoption rate of technologically advanced products is high. For instance, in March 2022, Beckman Coulter (a Danaher Corporation company) (US) launched CellMek SPS, a fully automated sample preparation system for clinical flow cytometry.
Opportunities: Public-private funding initiatives in stem cell research
Owing to these advantages, the adoption of flow cytometry for stem cell research has increased significantly during the last decade. Aside from the favourable regulatory environment in emerging countries, many stem cell product pipelines and increased use of stem cells in the treatment of various diseases drive global stem cell research activities. This is also supported by the increasing number of research activities and financial support from public-private organizations in the stem cell research industry. As of September 2021, the California Institute for Regenerative Medicine (US) has awarded USD 31 million to three Stanford University (US) researchers to launch first-in-human trials of stem cells to treat stroke, heart failure, and a type of brain and spinal cord tumor.
Restraints: High product costs
Most end users, such as clinical laboratories, large research facilities, and pharmaceutical companies, require many flow cytometry instruments to simultaneously carry out multiple research studies. This leads to a significant increase in the capital cost associated with the procurement and maintenance of these devices. In addition, maintenance costs and several other indirect expenses result in an overall increase in the total cost of ownership of these instruments. Thus, high product installation costs and related expenditures hinder the optimal adoption of flow cytometry instruments in clinical and research applications, especially in emerging nations. In addition, flow cytometry instruments are equipped with advanced features and functionalities, thus making them high-priced instruments. However, flow cytometry-based cell sorters are more expensive than cell analyzers. For instance, as of July 2021, the average cost of a flow cytometer varies between USD 100,000 to USD 500,000 for a single unit.
Academic & research institutes held a dominant share in end user segment in Flow Cytometry market
Based on end users, the global market is segmented into academic and research institutes, hospitals and clinical testing laboratories, and pharmaceutical and biotechnology companies. The academic and research institutes segment accounted for the largest market share in 2021. The growing focus of academic institutions on developing assays for innovative applications drives the demand for flow cytometry products in this end-user segment. Additionally, growing investments by pharmaceutical companies in academic research further support market growth.
The idiopathic overactive bladder dominated the Flow Cytometry market in 2021
Based on disease type, the global market is segmented into idiopathic and neurogenic overactive bladder syndromes. The idiopathic overactive bladder syndrome segment accounted for a larger market share due to the higher prevalence of idiopathic overactive bladder disorders. Furthermore, increased use of SNM therapy for patients with idiopathic overactive bladder is anticipated to contribute to segmental growth.
North America accounted for largest share in Flow Cytometry market in 2021
Geographically, the global market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America held the dominant share, followed by Europe. The North American market is mature, with high penetration of flow cytometry technologies among key end users. However, this market is still expected to offer high growth opportunities because of the expanding application areas of flow cytometry in clinical settings. Factors such as the presence of a favourable business environment, growing government support through funds and grants, the high prevalence of HIV/AIDS and cancer, the growing focus on the development of treatment options for target diseases (such as cancer and immunological disorders), and the strong presence of key players are driving the growth of the market in the region.
To know about the assumptions considered for the study, download the pdf brochure
Key players in the global flow cytometry market include Becton, Dickinson and Company (US), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Luminex Corporation (US), Agilent Technologies, Inc. (US), Sony Group Corporation (Japan), Bio-Rad Laboratories, Inc. (US), and among others
Flow Cytometry Market Report Scope
|
Report Metric |
Details |
|
Market Revenue in 2022 |
$4.7 billion |
|
Estimated Value by 2027 |
$6.9 billion |
|
Growth Rate |
Poised to grow at a CAGR of 8.1% |
|
Largest Share Segments |
|
|
Market Report Segmentation |
Technology, Product and Service, Application, End User And Regional |
|
Growth Drivers |
|
|
Growth Opportunities |
|
|
Geographies covered |
North America, Europe, APAC, MEA, and Latin America |
This report categorizes the global Flow Cytometry Market into following segments & sub-segments:
By Technology
- Cell-based Flow Cytometry
- Bead-based Flow Cytometry
By Product and Service
- Reagents and Consumables
-
Instruments
-
Cell Analyzers
- High-range
- Mid-range
- Low-range
-
Cell Sorters
- High-range
- Mid-range
- Low-range
-
Cell Analyzers
- Services
- Software
- Accessories
By Application
-
Research Applications
-
Pharmaceuticals and Biotechnology
- Drug Discovery
- Stem Cell Research
- In Vitro Toxicity Testing
- Immunology
- Cell Sorting
- Apoptosis
- Cell Cycle Analysis
- Cell Viability
- Cell Counting
- Other Research Applications
-
Pharmaceuticals and Biotechnology
-
Clinical Applications
- Cancer Diagnostics
- Hematology
- Autoimmune Diseases
- Organ Transplantation
- Other Clinical Applications
- Industrial Applications
By End User
- Academic & Research Institutes
- Hospitals & Clinical Testing Laboratories
- Pharmaceutical & Biotechnology Companies
By Region
-
North America
- US
- Canada
-
Europe
- Germany
- France
- Italy
- Spain
- UK
- Rest of Europe
-
Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Singapore
- Indonesia
- Rest of Asia Pacific
-
Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
Recent Developments
- In June 2022, BD (US) launched BD FACSDiscover S8 Cell Sorter with high-speed imaging technology that sorts cells based on visual characteristics.
- In March 2022, Beckman Coulter, Inc. (US) launched a fully automated sample preparation system (SPS) CellMek SPS, which offers on-demand processing for many sample types to help laboratories expand capabilities
Frequently Asked Questions (FAQ):
What is the projected market value of the global flow cytometry market?
The global market of flow cytometry is projected to reach USD 6.9 billion.
What is the estimated growth rate (CAGR) of the global flow cytometry market for the next five years?
The global flow cytometry market in terms of revenue was estimated to be worth $4.7 billion in 2022 and is poised to grow at a CAGR of 8.1%.
What are the major revenue pockets in the flow cytometry market currently?
Geographically, the global market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America held the dominant share, followed by Europe. The North American market is mature, with high penetration of flow cytometry technologies among key end users. However, this market is still expected to offer high growth opportunities because of the expanding application areas of flow cytometry in clinical settings. Factors such as the presence of a favourable business environment, growing government support through funds and grants, the high prevalence of HIV/AIDS and cancer, the growing focus on the development of treatment options for target diseases (such as cancer and immunological disorders), and the strong presence of key players are driving the growth of the market in the region.
To speak to our analyst for a discussion on the above findings, click Speak to Analyst
TABLE OF CONTENTS
1 INTRODUCTION (Page No. - 43)
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED
1.3.2 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 LIMITATIONS
1.6 STAKEHOLDERS
1.7 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY (Page No. - 48)
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY DATA
2.1.2 PRIMARY DATA
FIGURE 2 FLOW CYTOMETRY MARKET: BREAKDOWN OF PRIMARIES
2.2 MARKET ESTIMATION METHODOLOGY
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION
FIGURE 3 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS (2021)
FIGURE 4 AVERAGE MARKET SIZE ESTIMATION (2021)
2.3 DATA TRIANGULATION APPROACH
FIGURE 5 DATA TRIANGULATION METHODOLOGY
2.4 GROWTH FORECAST
2.5 LIMITATIONS
2.6 RISK ASSESSMENT
2.7 CAGR PROJECTIONS
2.7.1 SUPPLY-SIDE ANALYSIS
2.7.2 DEMAND-SIDE ANALYSIS
2.7.3 INSIGHTS FROM PRIMARY EXPERTS
3 EXECUTIVE SUMMARY (Page No. - 58)
FIGURE 6 FLOW CYTOMETRY MARKET, BY PRODUCT & SERVICE, 2022 VS. 2027 (USD MILLION)
FIGURE 7 GLOBAL MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION)
FIGURE 8 GLOBAL MARKET, BY END USER, 2021
FIGURE 9 GEOGRAPHICAL SNAPSHOT
4 PREMIUM INSIGHTS (Page No. - 61)
4.1 FLOW CYTOMETRY MARKET OVERVIEW
FIGURE 10 INCREASING PREVALENCE OF AUTOIMMUNE DISEASES AND RISING ADVANCEMENTS IN FLOW CYTOMETRY TECHNIQUES DRIVE MARKET GROWTH
4.2 ASIA PACIFIC: MARKET SHARE, BY PRODUCT & SERVICE (2021)
FIGURE 11 REAGENTS & CONSUMABLES SEGMENT ACCOUNTED FOR LARGEST SHARE IN 2021
4.3 GLOBAL MARKET SHARE, BY TECHNOLOGY, 2022 VS. 2027
FIGURE 12 CELL-BASED FLOW CYTOMETRY SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.4 GLOBAL MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 13 CHINA TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
5 MARKET OVERVIEW (Page No. - 65)
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 14 FLOW CYTOMETRY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Increasing incidence of HIV/AIDS and cancer
TABLE 1 INCIDENCE OF HIV/AIDS, BY REGION, 2020
TABLE 2 CANCER INCIDENCE, 2020 VS. 2040
5.2.1.2 Flow cytometry techniques in research activities
5.2.1.3 Use of flow cytometry in regenerative medicine
5.2.1.4 Growing public−private initiatives in immunology and immuno-oncology research
5.2.1.5 Technological advancements in flow cytometry instruments
TABLE 3 IMPORTANT TECHNOLOGICAL ADVANCEMENTS (2019–2022)
5.2.2 RESTRAINTS
5.2.2.1 High product cost
5.2.3 OPPORTUNITIES
5.2.3.1 Emerging markets
5.2.3.2 Public-private funding initiatives in stem cell research
TABLE 4 NIH-ESTIMATED STEM CELL RESEARCH EXPENDITURE DATA
5.2.3.3 Adoption of recombinant DNA technology for antibody production
5.2.4 CHALLENGES
5.2.4.1 Complexities related to reagent development
5.2.4.2 Shortage of well-trained and skilled professionals
5.3 PATENT ANALYSIS
5.3.1 LIST OF MAJOR PATENTS
5.4 SUPPLY CHAIN ANALYSIS
FIGURE 15 DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES
5.4.1 KEY INFLUENCERS
5.5 VALUE CHAIN ANALYSIS
FIGURE 16 FLOW CYTOMETRY MARKET: VALUE CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
FIGURE 17 GLOBAL MARKET: ECOSYSTEM ANALYSIS
5.6.1 ROLE IN ECOSYSTEM
5.7 REGULATORY ASSESSMENT
5.7.1 STRINGENT FDA REQUIREMENTS
5.7.2 ANALYTE-SPECIFIC REAGENT RULE
5.7.3 LIMITATIONS IN VALIDATION PROTOCOLS FOR CELL-BASED ASSAYS
5.7.4 ABSENCE OF TEST GUIDELINES ON CELL-BASED FLUORESCENCE ASSAYS
5.7.5 IVD CE MARK APPROVALS
5.7.6 US: REIMBURSEMENT SCENARIO
5.8 PORTER’S FIVE FORCES ANALYSIS
TABLE 5 GLOBAL MARKET- PORTER’S FIVE FORCES ANALYSIS
5.8.1 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
5.8.2 BARGAINING POWER OF SUPPLIERS
5.8.3 BARGAINING POWER OF BUYERS
5.8.4 THREAT OF SUBSTITUTES
5.8.5 THREAT OF NEW ENTRANTS
5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 18 REVENUE SHIFT & NEW REVENUE POCKETS FOR FLOW CYTOMETRY MARKET
5.10 KEY CONFERENCES & EVENTS IN 2022-2023
TABLE 6 GLOBAL MARKET: DETAILED LIST OF EVENTS AND CONFERENCES
5.11 TRADE DATA
TABLE 7 IMPORT DATA FOR FLOW CYTOMETERS, BY COUNTRY, 2017–2021 (USD THOUSAND)
TABLE 8 IMPORT DATA FOR FLOW CYTOMETERS, BY COUNTRY, 2017–2021 (USD THOUSAND)
5.12 PRICING ANALYSIS
TABLE 9 COST OF FLOW CYTOMETERS, BY TYPE
TABLE 10 COST OF FLOW CYTOMETERS & OTHER PRODUCTS, BY COMPANY
5.12.1 COST OF FLOW CYTOMETRY SOFTWARE
5.13 KEY STAKEHOLDERS AND BUYING CRITERIA
FIGURE 19 KEY STAKEHOLDERS IN PHARMACEUTICAL COMPANIES AND INFLUENCES ON BUYING PROCESSES
FIGURE 20 KEY BUYING CRITERIA FOR FLOW CYTOMETRY PRODUCTS AMONG END USERS
6 FLOW CYTOMETRY MARKET, BY TECHNOLOGY (Page No. - 89)
6.1 INTRODUCTION
TABLE 11 GLOBAL MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
6.2 CELL-BASED FLOW CYTOMETRY
6.2.1 RISING R&D INVESTMENTS FOR NEW THERAPEUTIC AGENTS TO DRIVE MARKET GROWTH
TABLE 12 CELL-BASED MARKET, BY REGION, 2020–2027 (USD MILLION)
6.3 BEAD-BASED FLOW CYTOMETRY
6.3.1 HIGH RELIABILITY AND MEASUREMENT CONSISTENCIES OF BEAD-BASED FLOW CYTOMETRY TO SUPPORT GROWTH
TABLE 13 BEAD-BASED MARKET, BY REGION, 2020–2027 (USD MILLION)
7 FLOW CYTOMETRY MARKET, BY PRODUCT & SERVICE (Page No. - 93)
7.1 INTRODUCTION
TABLE 14 GLOBAL MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
7.2 REAGENTS & CONSUMABLES
7.2.1 INCREASING INVESTMENTS IN RESEARCH TO DRIVE MARKET DEMAND
TABLE 15 FLOW CYTOMETRY REAGENTS & CONSUMABLES MARKET, BY REGION, 2020–2027 (USD MILLION)
7.3 INSTRUMENTS
7.3.1 LAUNCH OF TECHNOLOGICALLY ADVANCED INSTRUMENTS TO PROPEL MARKET GROWTH
TABLE 16 FLOW CYTOMETRY INSTRUMENTS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 17 FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
7.3.2 CELL ANALYZERS
7.3.2.1 Investments by leading market players in developing cell analyzers to drive market growth
TABLE 18 FLOW CYTOMETRY-BASED CELL ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 19 FLOW CYTOMETRY-BASED CELL ANALYZERS MARKET, BY PRICE RANGE, 2020–2027 (USD MILLION)
7.3.2.2 High-range cell analyzers
7.3.2.2.1 Wide adoption of high-range cell analyzers among end users to drive market growth
TABLE 20 HIGH-RANGE CELL ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION)
7.3.2.3 Mid-range cell analyzers
7.3.2.3.1 Availability of compact & high-performance analyzers to support market growth
TABLE 21 MID-RANGE CELL ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION)
7.3.2.4 Low-range cell analyzers
7.3.2.4.1 Low-range analyzers significantly adopted among price-sensitive end users
TABLE 22 LOW-RANGE CELL ANALYZERS MARKET, BY REGION, 2020–2027 (USD MILLION)
7.3.3 CELL SORTERS
TABLE 23 FLOW CYTOMETRY-BASED CELL SORTERS MARKET, BY REGION, 2020–2027 (USD MILLION)
TABLE 24 FLOW CYTOMETRY-BASED CELL SORTERS MARKET, BY PRICE RANGE, 2020–2027 (USD MILLION)
7.3.3.1 High-range cell sorters
7.3.3.1.1 High cost and budgetary limitations to restrain market growth
TABLE 25 HIGH-RANGE CELL SORTERS MARKET, BY REGION, 2020–2027 (USD MILLION)
7.3.3.2 Mid-range cell sorters
7.3.3.2.1 Cost-efficiency & frequent product launches for mid-range sorters to drive market growth
TABLE 26 MID-RANGE CELL SORTERS MARKET, BY REGION, 2020–2027 (USD MILLION)
7.3.3.3 Low-range cell sorters
7.3.3.3.1 Small-scale labs and research facilities to be major end users of low-range sorters
TABLE 27 LOW-RANGE CELL SORTERS MARKET, BY REGION, 2020–2027 (USD MILLION)
7.4 SERVICES
7.4.1 FLOW CYTOMETRY SERVICES TO ENSURE WORKFLOW CONTINUITY AND MAXIMIZE PERFORMANCE
TABLE 28 FLOW CYTOMETRY SERVICES MARKET, BY REGION, 2020–2027 (USD MILLION)
7.5 SOFTWARE
7.5.1 TECHNOLOGICAL ADVANCEMENTS IN SOFTWARE TO DRIVE MARKET GROWTH
TABLE 29 FLOW CYTOMETRY SOFTWARE MARKET, BY REGION, 2020–2027 (USD MILLION)
7.6 ACCESSORIES
7.6.1 PROCEDURAL BENEFITS OFFERED BY FLOW CYTOMETRY ACCESSORIES TO SUPPORT MARKET GROWTH
TABLE 30 FLOW CYTOMETRY ACCESSORIES MARKET, BY REGION, 2020–2027 (USD MILLION)
8 FLOW CYTOMETRY MARKET, BY APPLICATION (Page No. - 106)
8.1 INTRODUCTION
TABLE 31 GLOBAL MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
8.2 RESEARCH APPLICATIONS
TABLE 32 GLOBAL MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 33 GLOBAL MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
8.2.1 PHARMACEUTICAL & BIOTECHNOLOGY
TABLE 34 GLOBAL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY, BY TYPE, 2020–2027 (USD MILLION)
8.2.1.1 Drug discovery
8.2.1.1.1 Growing use of phenotypic cell-based assays in drug discovery to support market growth
TABLE 35 GLOBAL MARKET FOR DRUG DISCOVERY, BY REGION, 2020–2027 (USD MILLION)
8.2.1.2 Stem cell research
8.2.1.2.1 Increasing investments in stem cell research to drive demand for flow cytometry products
TABLE 36 GLOBAL MARKET FOR STEM CELL RESEARCH, BY REGION, 2020–2027 (USD MILLION)
8.2.1.3 In vitro toxicity testing
8.2.1.3.1 Growing adoption of flow cytometry in drug discovery & development to support market growth
TABLE 37 FLOW CYTOMETRY MARKET FOR IN VITRO TOXICITY TESTING, BY REGION, 2020–2027 (USD MILLION)
8.2.2 IMMUNOLOGY
8.2.2.1 Growing prevalence of infectious & autoimmune diseases to support market growth
TABLE 38 GLOBAL MARKET FOR IMMUNOLOGY, BY REGION, 2020–2027 (USD MILLION)
8.2.3 CELL SORTING
8.2.3.1 Technologically advanced cell sorters to drive market growth
TABLE 39 GLOBAL MARKET FOR CELL SORTING, BY REGION, 2020–2027 (USD MILLION)
8.2.4 APOPTOSIS
8.2.4.1 Growing use of apoptosis assays to support market growth
TABLE 40 GLOBAL MARKET FOR APOPTOSIS, BY REGION, 2020–2027 (USD MILLION)
8.2.5 CELL CYCLE ANALYSIS
8.2.5.1 Use of flowcytometry to detect chromosomal abnormalities
TABLE 41 GLOBAL MARKET FOR CELL CYCLE ANALYSIS, BY REGION, 2020–2027 (USD MILLION)
8.2.6 CELL VIABILITY
8.2.6.1 Growing use of cell viability assays in research to support market growth
TABLE 42 GLOBAL MARKET FOR CELL VIABILITY, BY REGION, 2020–2027 (USD MILLION)
8.2.7 CELL COUNTING
8.2.7.1 Flow cytometry permits easy differentiation of cells via scattering or staining
TABLE 43 FLOW CYTOMETRY MARKET FOR CELL COUNTING, BY REGION, 2020–2027 (USD MILLION)
8.2.8 OTHER RESEARCH APPLICATIONS
TABLE 44 GLOBAL MARKET FOR OTHER RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
8.3 CLINICAL APPLICATIONS
TABLE 45 GLOBAL MARKET FOR CLINICAL APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION)
TABLE 46 GLOBAL MARKET FOR CLINICAL APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
8.3.1 CANCER
8.3.1.1 Growing use of flow cytometry techniques in cancer predictions to drive market growth
TABLE 47 ESTIMATED NUMBER OF NEW CANCER CASES (2020–2040)
TABLE 48 GLOBAL MARKET FOR CANCER, BY REGION, 2020–2027 (USD MILLION)
8.3.2 HEMATOLOGY
8.3.2.1 Increasing use of flow cytometry in hematology applications to drive market growth
TABLE 49 GLOBAL MARKET FOR HEMATOLOGY, BY REGION, 2020–2027 (USD MILLION)
8.4 IMMUNODEFICIENCY DISEASES
8.4.1 BENEFITS OF FLOW CYTOMETRY IN DIAGNOSIS OF IMMUNODEFICIENCY DISEASES TO DRIVE MARKET GROWTH
TABLE 50 APPLICATION OF FLOW CYTOMETRY IN DIAGNOSIS OF PRIMARY IMMUNODEFICIENCY DISEASES.
TABLE 51 FLOW CYTOMETRY MARKET FOR IMMUNODEFICIENCY DISEASE, BY REGION, 2020–2027 (USD MILLION)
8.4.2 ORGAN & TISSUE TRANSPLANTATION
8.4.2.1 Increasing organ transplants worldwide to drive market growth
TABLE 52 GLOBAL MARKET FOR ORGAN TRANSPLANTATION, BY REGION, 2020–2027 (USD MILLION)
8.4.3 OTHER CLINICAL APPLICATIONS
TABLE 53 GLOBAL MARKET FOR OTHER CLINICAL APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
8.5 INDUSTRIAL APPLICATIONS
8.5.1 GROWING USE OF FLOW CYTOMETRY TECHNIQUES IN FOOD & DIARY TO SUPPORT MARKET GROWTH
TABLE 54 GLOBAL MARKET FOR INDUSTRIAL APPLICATIONS, BY REGION, 2020–2027 (USD MILLION)
9 FLOW CYTOMETRY MARKET, BY END USER (Page No. - 126)
9.1 INTRODUCTION
TABLE 55 GLOBAL MARKET, BY END USER, 2020–2027 (USD MILLION)
9.2 ACADEMIC & RESEARCH INSTITUTES
9.2.1 GROWING COLLABORATIONS AMONG ACADEMIC & RESEARCH INSTITUTES EXPECTED TO DRIVE MARKET
TABLE 56 GLOBAL MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION)
9.3 HOSPITALS & CLINICAL TESTING LABORATORIES
9.3.1 USE OF FLOW CYTOMETRY TECHNIQUES IN INFECTIOUS DISEASE DIAGNOSTICS TO DRIVE MARKET GROWTH
TABLE 57 GLOBAL MARKET FOR HOSPITALS & CLINICAL TESTING LABORATORIES, BY REGION, 2020–2027 (USD MILLION)
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
9.4.1 INCREASING INVESTMENTS IN DRUG DISCOVERY & DEVELOPMENT TO SUPPORT MARKET GROWTH
TABLE 58 GLOBAL MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION)
10 FLOW CYTOMETRY MARKET, BY REGION (Page No. - 131)
10.1 INTRODUCTION
TABLE 59 GLOBAL MARKET, BY REGION, 2020–2027 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 21 NORTH AMERICA: FLOW CYTOMETRY MARKET SNAPSHOT
TABLE 60 NORTH AMERICA: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 61 NORTH AMERICA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 62 NORTH AMERICA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 63 NORTH AMERICA: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 64 NORTH AMERICA: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 65 NORTH AMERICA: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 66 NORTH AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 67 NORTH AMERICA: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 68 NORTH AMERICA: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 69 NORTH AMERICA: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 70 NORTH AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2.1 US
10.2.1.1 High incidence of cancer and HIV-AIDS to drive market growth
TABLE 71 US: FLOW CYTOMETRY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 72 US: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 73 US: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 74 US: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 75 US: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 76 US: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 77 US: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 78 US: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 79 US: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 80 US: MARKET, BY END USER, 2020–2027 (USD MILLION)
10.2.2 CANADA
10.2.2.1 Ongoing government initiatives for life science research to drive demand
TABLE 81 CANADA: FLOW CYTOMETRY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 82 CANADA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 83 CANADA: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 84 CANADA: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 85 CANADA: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 86 CANADA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 87 CANADA: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 88 CANADA: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 89 CANADA: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 90 CANADA: MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3 EUROPE
TABLE 91 EUROPE: FLOW CYTOMETRY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 92 EUROPE: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 93 EUROPE: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 94 EUROPE: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 95 EUROPE: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 96 EUROPE: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 97 EUROPE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 98 EUROPE: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 99 EUROPE: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 100 EUROPE: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 101 EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.1 GERMANY
10.3.1.1 Strong research & development infrastructure and awareness programs on flow cytometry to ensure market growth
TABLE 102 GERMANY: FLOW CYTOMETRY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 103 GERMANY: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 104 GERMANY: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 105 GERMANY: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 106 GERMANY: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 107 GERMANY: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 108 GERMANY: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 109 GERMANY: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 110 GERMANY: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 111 GERMANY: MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.2 UK
10.3.2.1 Acceptance of flow cytometry products for clinical applications to propel market growth
TABLE 112 UK: FLOW CYTOMETRY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 113 UK: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 114 UK: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 115 UK: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 116 UK: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 117 UK: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 118 UK: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 119 UK: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 120 UK: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 121 UK: MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Strong government funding for proteomics & genomics research to drive market growth
TABLE 122 FRANCE: FLOW CYTOMETRY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 123 FRANCE: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 124 FRANCE: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 125 FRANCE: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 126 FRANCE: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 127 FRANCE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 128 FRANCE: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 129 FRANCE: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 130 FRANCE: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 131 FRANCE: MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.4 ITALY
10.3.4.1 Rising geriatric population and increasing activities in life science to drive market growth
TABLE 132 ITALY: FLOW CYTOMETRY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 133 ITALY: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 134 ITALY: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 135 ITALY: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 136 ITALY: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 137 ITALY: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 138 ITALY: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 139 ITALY: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 140 ITALY: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 141 ITALY: MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.5 SPAIN
10.3.5.1 Growing focus on cancer diagnosis to drive demand
TABLE 142 SPAIN: FLOW CYTOMETRY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 143 SPAIN: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 144 SPAIN: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 145 SPAIN: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 146 SPAIN: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 147 SPAIN: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 148 SPAIN: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 149 SPAIN: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 150 SPAIN: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 151 SPAIN: MARKET, BY END USER, 2020–2027 (USD MILLION)
10.3.6 REST OF EUROPE (ROE)
TABLE 152 REST OF EUROPE: FLOW CYTOMETRY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 153 REST OF EUROPE: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 154 REST OF EUROPE: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 155 REST OF EUROPE: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 156 REST OF EUROPE: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 157 REST OF EUROPE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 158 REST OF EUROPE: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 159 REST OF EUROPE: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 160 REST OF EUROPE: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 161 REST OF EUROPE: MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 22 ASIA PACIFIC: FLOW CYTOMETRY MARKET SNAPSHOT
TABLE 162 ASIA PACIFIC: MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 163 ASIA PACIFIC: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 164 ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 165 ASIA PACIFIC: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 166 ASIA PACIFIC: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 167 ASIA PACIFIC: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 168 ASIA PACIFIC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 169 ASIA PACIFIC: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 170 ASIA PACIFIC: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 171 ASIA PACIFIC: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 172 ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.1 JAPAN
10.4.1.1 Increasing research on flow cytometry-based techniques to drive market growth
TABLE 173 JAPAN: FLOW CYTOMETRY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 174 JAPAN: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 175 JAPAN: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 176 JAPAN: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 177 JAPAN: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 178 JAPAN: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 179 JAPAN: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 180 JAPAN: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 181 JAPAN: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 182 JAPAN: MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.2 CHINA
10.4.2.1 High incidence of target diseases and growing presence of global players to drive market growth
TABLE 183 CHINA: FLOW CYTOMETRY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 184 CHINA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 185 CHINA: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 186 CHINA: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 187 CHINA: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 188 CHINA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 189 CHINA: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 190 CHINA: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 191 CHINA: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 192 CHINA: MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.3 INDIA
10.4.3.1 Rising government funding for research activities in proteomics technologies to drive market growth
TABLE 193 INDIA: FLOW CYTOMETRY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 194 INDIA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 195 INDIA: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 196 INDIA: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 197 INDIA: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 198 INDIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 199 INDIA: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 200 INDIA: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 201 INDIA: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 202 INDIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.4 AUSTRALIA
10.4.4.1 Uptake of flow cytometry techniques to conduct cancer-related research to support market growth
TABLE 203 AUSTRALIA: FLOW CYTOMETRY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 204 AUSTRALIA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 205 AUSTRALIA: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 206 AUSTRALIA: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 207 AUSTRALIA: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 208 AUSTRALIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 209 AUSTRALIA: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 210 AUSTRALIA: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 211 AUSTRALIA: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 212 AUSTRALIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.5 SOUTH KOREA
10.4.5.1 Increasing awareness initiatives on flow cytometry to support market growth
TABLE 213 SOUTH KOREA: FLOW CYTOMETRY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 214 SOUTH KOREA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 215 SOUTH KOREA: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 216 SOUTH KOREA: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 217 SOUTH KOREA: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 218 SOUTH KOREA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 219 SOUTH KOREA: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 220 SOUTH KOREA: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 221 SOUTH KOREA: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 222 SOUTH KOREA: MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.6 SINGAPORE
10.4.6.1 Launch of novel technologies for flow cytometry research to support market growth
TABLE 223 SINGAPORE: FLOW CYTOMETRY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 224 SINGAPORE: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 225 SINGAPORE: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 226 SINGAPORE: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 227 SINGAPORE: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 228 SINGAPORE: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 229 SINGAPORE: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 230 SINGAPORE: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 231 SINGAPORE: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 232 SINGAPORE: MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.7 INDONESIA
10.4.7.1 Rising prevalence of HIV and cancer to drive demand
TABLE 233 INDONESIA: FLOW CYTOMETRY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 234 INDONESIA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 235 INDONESIA: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 236 INDONESIA: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 237 INDONESIA: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 238 INDONESIA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 239 INDONESIA: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 240 INDONESIA: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 241 INDONESIA: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 242 INDONESIA: MARKET, BY END USER, 2020–2027 (USD MILLION)
10.4.8 REST OF ASIA PACIFIC (ROAPAC)
TABLE 243 REST OF ASIA PACIFIC: FLOW CYTOMETRY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 244 REST OF ASIA PACIFIC: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 245 REST OF ASIA PACIFIC: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 246 REST OF ASIA PACIFIC: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 247 REST OF ASIA PACIFIC: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 248 REST OF ASIA PACIFIC: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 249 REST OF ASIA PACIFIC: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 250 REST OF ASIA PACIFIC: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 251 REST OF ASIA PACIFIC: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 252 REST OF ASIA PACIFIC: MARKET, BY END USER, 2020–2027 (USD MILLION)
10.5 LATIN AMERICA
TABLE 253 LATIN AMERICA: FLOW CYTOMETRY MARKET, BY COUNTRY, 2020–2027 (USD MILLION)
TABLE 254 LATIN AMERICA: MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 255 LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 256 LATIN AMERICA: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 257 LATIN AMERICA: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 258 LATIN AMERICA: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 259 LATIN AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 260 LATIN AMERICA: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 261 LATIN AMERICA: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 262 LATIN AMERICA: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 263 LATIN AMERICA: MARKET, BY END USER, 2020–2027 (USD MILLION)
10.5.1 BRAZIL
10.5.1.1 Well-established presence of key market players ensures adoption of flow cytometry products
TABLE 264 BRAZIL: FLOW CYTOMETRY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 265 BRAZIL: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 266 BRAZIL: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 267 BRAZIL: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 268 BRAZIL: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 269 BRAZIL: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 270 BRAZIL: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 271 BRAZIL: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 272 BRAZIL: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 273 BRAZIL: MARKET, BY END USER, 2020–2027 (USD MILLION)
10.5.2 MEXICO
10.5.2.1 Favorable trade agreements to support availability of flow cytometry products
TABLE 274 MEXICO: FLOW CYTOMETRY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 275 MEXICO: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 276 MEXICO: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 277 MEXICO: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 278 MEXICO: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 279 MEXICO: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 280 MEXICO: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 281 MEXICO: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 282 MEXICO: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 283 MEXICO: FLOW CYTOMETRY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.5.3 REST OF LATIN AMERICA (ROLATAM)
TABLE 284 REST OF LATIN AMERICA: FLOW CYTOMETRY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 285 REST OF LATIN AMERICA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 286 REST OF LATIN AMERICA: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 287 REST OF LATIN AMERICA: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 288 REST OF LATIN AMERICA: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 289 REST OF LATIN AMERICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 290 REST OF LATIN AMERICA: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 291 REST OF LATIN AMERICA: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 292 REST OF LATIN AMERICA: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 293 REST OF LATIN AMERICA: FLOW CYTOMETRY MARKET, BY END USER, 2020–2027 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 GROWING RESEARCH COLLABORATIONS AND RISING FUNDING INITIATIVES TO DRIVE MARKET GROWTH
TABLE 294 MIDDLE EAST & AFRICA: FLOW CYTOMETRY MARKET, BY TECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 295 MIDDLE EAST & AFRICA: MARKET, BY PRODUCT & SERVICE, 2020–2027 (USD MILLION)
TABLE 296 MIDDLE EAST & AFRICA: FLOW CYTOMETRY INSTRUMENTS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 297 MIDDLE EAST & AFRICA: FLOW CYTOMETRY CELL ANALYZERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 298 MIDDLE EAST & AFRICA: FLOW CYTOMETRY CELL SORTERS MARKET, BY TYPE, 2020–2027 (USD MILLION)
TABLE 299 MIDDLE EAST & AFRICA: MARKET, BY APPLICATION, 2020–2027 (USD MILLION)
TABLE 300 MIDDLE EAST & AFRICA: MARKET, BY RESEARCH APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 301 MIDDLE EAST & AFRICA: MARKET, BY PHARMACEUTICAL & BIOTECHNOLOGY, 2020–2027 (USD MILLION)
TABLE 302 MIDDLE EAST & AFRICA: MARKET, BY CLINICAL APPLICATIONS, 2020–2027 (USD MILLION)
TABLE 303 MIDDLE EAST & AFRICA: FLOW CYTOMETRY MARKET, BY END USER, 2020–2027 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 251)
11.1 INTRODUCTION
11.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
TABLE 304 FLOW CYTOMETRY MARKET: STRATEGIES ADOPTED
11.3 REVENUE ANALYSIS
FIGURE 23 REVENUE ANALYSIS FOR KEY COMPANIES (2019–2021)
11.4 MARKET SHARE ANALYSIS
FIGURE 24 GLOBAL MARKET SHARE ANALYSIS, BY KEY PLAYER, 2021
TABLE 305 GLOBAL MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION QUADRANT
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 25 GLOBAL MARKET: COMPETITIVE LEADERSHIP MAPPING, 2021
11.6 COMPETITIVE LEADERSHIP MAPPING: EMERGING COMPANIES/SMES/START-UPS (2021)
11.6.1 PROGRESSIVE COMPANIES
11.6.2 STARTING BLOCKS
11.6.3 RESPONSIVE COMPANIES
11.6.4 DYNAMIC COMPANIES
FIGURE 26 FLOW CYTOMETRY MARKET: COMPETITIVE LEADERSHIP MAPPING FOR SMES/START-UPS, 2021
11.7 COMPETITIVE BENCHMARKING
11.7.1 COMPANY FOOTPRINT
TABLE 306 COMPANY PRODUCT FOOTPRINT
TABLE 307 COMPANY REGIONAL FOOTPRINT
11.8 COMPETITIVE SCENARIO AND TRENDS
TABLE 308 GLOBAL MARKET: PRODUCT LAUNCHES & ENHANCEMENTS (JANUARY 2019-JULY 2022)
TABLE 309 FLOW CYTOMETRY MARKET: DEALS, JANUARY 2019–JULY 2022
12 COMPANY PROFILES (Page No. - 264)
(Business overview, Products offered, Recent Developments, MNM view)*
12.1 KEY PLAYERS
12.1.1 BD
TABLE 310 BD: BUSINESS OVERVIEW
FIGURE 27 BD: COMPANY SNAPSHOT (2021)
12.1.2 DANAHER CORPORATION
TABLE 311 DANAHER CORPORATION: BUSINESS OVERVIEW
FIGURE 28 DANAHER CORPORATION: COMPANY SNAPSHOT (2021)
12.1.3 THERMO FISHER SCIENTIFIC, INC.
TABLE 312 THERMO FISHER SCIENTIFIC, INC: BUSINESS OVERVIEW
FIGURE 29 THERMO FISHER SCIENTIFIC, INC: COMPANY SNAPSHOT (2021)
12.1.4 AGILENT TECHNOLOGIES, INC
TABLE 313 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW
FIGURE 30 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2021)
12.1.5 SONY BIOTECHNOLOGY INC. (A SUBSIDIARY OF SONY GROUP CORPORATION)
TABLE 314 SONY GROUP CORPORATION: BUSINESS OVERVIEW
FIGURE 31 SONY GROUP CORPORATION: COMPANY SNAPSHOT (2021)
12.1.6 BIO-RAD LABORATORIES INC.
TABLE 315 BIO-RAD LABORATORIES INC: BUSINESS OVERVIEW
FIGURE 32 BIO-RAD LABORATORIES INC: COMPANY SNAPSHOT (2021)
12.1.7 MILTENYI BIOTEC
TABLE 316 MILTENYI BIOTEC: BUSINESS OVERVIEW
12.1.8 ENZO BIOCHEM, INC.
TABLE 317 ENZO BIOCHEM, INC.: BUSINESS OVERVIEW
FIGURE 33 ENZO BIOCHEM, INC: COMPANY SNAPSHOT (2021)
12.1.9 SYSMEX CORPORATION
TABLE 318 SYSMEX CORPORATION.: BUSINESS OVERVIEW
FIGURE 34 SYSMEX CORPORATION: COMPANY SNAPSHOT (2021)
12.1.10 LUMINEX CORPORATION (A DIASORIN COMPANY)
TABLE 319 DIASORIN S.P.A: BUSINESS OVERVIEW
FIGURE 35 DIASORIN S.P.A: COMPANY SNAPSHOT (2021)
12.1.11 BIOMÉRIEUX SA
TABLE 320 BIOMÉRIEUX SA.: BUSINESS OVERVIEW
FIGURE 36 BIOMÉRIEUX SA: COMPANY SNAPSHOT (2021)
12.1.12 CYTONOME/ST, LLC.
TABLE 321 CYTONOME/ST, LLC: BUSINESS OVERVIEW
12.1.13 SARTORIUS AG
TABLE 322 SARTORIUS AG.: BUSINESS OVERVIEW
FIGURE 37 SARTORIUS AG: COMPANY SNAPSHOT (2021)
TABLE 323 SARTORIUS AG: PRODUCT LAUNCHES
12.1.14 CYTEK BIOSCIENCES
TABLE 324 CYTEK BIOSCIENCES: BUSINESS OVERVIEW
FIGURE 38 CYTEK BIOSCIENCES: COMPANY SNAPSHOT (2021)
12.1.15 UNION BIOMETRICA, INC.
TABLE 325 UNION BIOMETRICA, INC.: BUSINESS OVERVIEW
12.2 OTHER PLAYERS
12.2.1 APOGEE FLOW SYSTEMS LTD.
TABLE 326 APOGEE FLOW SYSTEMS LTD: BUSINESS OVERVIEW
TABLE 327 APOGEE FLOW SYSTEMS: PRODUCTS & SERVICES OFFERED
12.2.2 STRATEDIGM, INC.
TABLE 328 STRATEDIGM, INC: BUSINESS OVERVIEW
TABLE 329 STRATEDIGM, INC: PRODUCT/SERVICE OFFERINGS
TABLE 330 STRATEDIGM: PRODUCT LAUNCHES AND ENHANCEMENTS
TABLE 331 STRATEDIGM, INC: DEALS
12.2.3 NANOCELLECT BIOMEDICAL, INC.
12.2.4 ON-CHIP BIOTECHNOLOGIES CO., LTD.
12.2.5 NEXCELOM BIOSCIENCE LLC.
12.2.6 BENNUBIO INC.
12.2.7 ORFLO TECHNOLOGIES
12.2.8 BAY BIOSCIENCE CO., LTD.
12.2.9 CYTOBUOY B.V.
12.2.10 BIOLEGEND, INC.
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 324)
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
This study involved four major activities in estimating the current size of the flow cytometry market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.
Secondary Research
Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the flow cytometry market. The secondary sources used for this study include World Health Organization (WHO), the Organization for Economic Co-operation and Development (OECD), the Global Cancer Observatory (GLOBOCAN), World Bank, Eurostat, the Joint United Nations Programme on HIV/AIDS (UNAIDS), the National Institutes of Health (NIH), Institute for Health Metrics and Evaluation (US), International Society for Advancement of Cytometry (US), US FDA, Health Canada, EuroStemCell, German Cancer Research Center, NHS (UK), Cancer Research UK (UK), Stem Cell Foundation, French National Research Agency (France), Italian National Institute of Health, National Cancer Center Japan, Ministry of Science & Technology (India), Australasian Cytometry Society (Australia), the Cytometry Society (India), International Clinical Cytometry Society (US), and African Cancer Registry Network; Lens. Org. National Center for Biotechnology Information (NCBI), corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, professional associations and among others. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess future prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Both top-down and bottom-up approaches were used to estimate and validate the total size of the flow cytometry market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive secondary research
- The revenues generated from the flow cytometry business of leading players have been determined through primary and secondary research
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources
Data Triangulation
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.
Report Objectives
- To define, describe, and forecast the global flow cytometry market based on the technology, product & service, application, end user and region
- To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, and opportunities)
- To strategically analyze micromarkets with respect to individual growth trends, future prospects, and contributions to the overall cell analysis market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to five main regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa
- To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the flow cytometry market.
Available Customizations
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Growth drivers for fluorescence-activated cell sorting business from macro to micro
The fluorescence-activated cell sorting (FACS) business has seen significant growth in recent years, driven by a range of macro and micro-level factors. Here are some of the growth drivers for the FACS business, from macro to micro
Technological advancements: The development of new technologies and innovations in the FACS field, such as the use of new fluorophores and improved software for data analysis, are driving growth in the industry.
Increasing demand for personalized medicine: The rising demand for personalized medicine, where individual patient cells are analyzed and sorted for the best treatment options, is driving growth in the FACS market.
Expanding applications in drug discovery: FACS technology is increasingly being used in drug discovery and development, driving growth in the industry.
Growth in the biopharmaceutical industry: The growth of the biopharmaceutical industry, which relies heavily on FACS technology for drug discovery and development, is driving growth in the FACS market.
Increasing prevalence of chronic diseases: The increasing prevalence of chronic diseases, such as cancer and autoimmune diseases, is driving demand for FACS-based diagnostic tests and cell-based therapies.
Growing demand for stem cell research: The growing demand for stem cell research, which relies heavily on FACS technology for cell sorting and analysis, is driving growth in the industry.
Increasing government funding for life sciences research: Government funding for life sciences research, including stem cell research and drug discovery, is driving growth in the FACS market.
Increasing adoption of single-cell analysis: The adoption of single-cell analysis, which relies heavily on FACS technology for sorting and analysis, is driving growth in the industry.
Growing demand for high-throughput screening: The demand for high-throughput screening, which requires FACS technology for cell sorting and analysis, is driving growth in the industry.
Overall, the FACS market is being driven by a range of macro and micro-level factors, from technological advancements and the growth of the biopharmaceutical industry to the increasing demand for personalized medicine and single-cell analysis. These drivers are expected to continue to fuel growth in the industry in the coming years.
Future hypothetic growth opportunities in fluorescence-activated cell sorting market
here are some top hypothetical growth opportunities in the fluorescence-activated cell sorting (FACS) market with examples
Application in infectious disease research and diagnostics: FACS technology can be used to analyze and sort cells from infectious diseases, such as HIV and COVID-19, providing insights into the immune response and potential targets for vaccines or therapies.
Application in neuroscience research: FACS technology can be used to sort and analyze cells from the nervous system, providing insights into neurodegenerative diseases and potential targets for therapies.
Expansion into developing markets: As the FACS market continues to grow in developed markets, there is potential for expansion into developing markets, where there is a growing demand for advanced life sciences technologies.
Integration with other technologies: FACS technology can be integrated with other technologies, such as genomics and proteomics, to provide a more complete picture of cell function and disease states.
Development of new types of fluorophores: The development of new types of fluorophores, such as quantum dots, could enhance the sensitivity and specificity of FACS analysis.
Adoption of machine learning and artificial intelligence: The adoption of machine learning and artificial intelligence in FACS analysis could enable more efficient and accurate data analysis and reduce the need for specialized expertise.
Expansion into clinical applications: While FACS is currently primarily used in research settings, there is potential for expansion into clinical applications, such as cancer diagnosis and cell-based therapies.
Integration with microfluidics technology: The integration of FACS technology with microfluidics technology could enable the analysis of smaller samples and increase the speed and efficiency of analysis.
Overall, the FACS market is expected to continue to see growth in a range of applications, including infectious disease research, neuroscience, and clinical applications. Continued innovation in FACS technology, such as the development of new fluorophores and integration with other technologies, is expected to drive growth in the industry.
Industry impact by fluorescence-activated cell sorting market in future
Fluorescence-activated cell sorting (FACS) technology has a wide range of applications in various industries, particularly in the fields of biomedical research, clinical diagnostics, and drug discovery. Here are a few industries that may heavily impact and be impacted by the FACS market in the future
Biopharmaceutical industry: FACS technology is commonly used in drug discovery and development, particularly in the discovery of new therapeutic targets and the screening of potential drug candidates. As the biopharmaceutical industry continues to grow, the demand for FACS technology is expected to increase.
Medical diagnostics: FACS technology can be used for the diagnosis and monitoring of various diseases, including cancer, immunodeficiency disorders, and autoimmune diseases. The demand for FACS-based diagnostic tests is expected to increase as healthcare systems continue to prioritize early detection and personalized medicine.
Academic and research institutions: FACS technology is widely used in academic and research institutions for a variety of applications, including stem cell research, immunology, and microbiology. As research in these fields continues to grow, the demand for FACS technology is likely to increase.
Food and beverage industry: FACS technology can be used in the food and beverage industry for quality control and safety testing, particularly for the detection of foodborne pathogens. As the demand for safe and high-quality food continues to grow, the use of FACS technology in this industry may also increase.
Overall, the FACS market is expected to continue to grow in the future as the demand for precise and reliable cell analysis and sorting increases across various industries.
Future use cases of fluorescence-activated cell sorting along with commentry of adaption, market potential, risk
The future use cases of fluorescence-activated cell sorting (FACS) technology are numerous and span multiple industries. Here are a few potential future use cases of FACS technology and some commentary on their adaptation, market potential, and associated risks
Personalized medicine: FACS technology has the potential to be used in the development of personalized medicine, where individual patient cells are sorted and analyzed to identify the best treatment options. The adoption of this application of FACS technology may be limited by the cost and complexity of the process, but the potential market is large as personalized medicine continues to gain traction.
Cell therapy: FACS technology can be used in the development of cell-based therapies, where specific cell types are sorted and used for the treatment of various diseases. The market potential for cell therapies is large, but the risks associated with this application of FACS technology include the potential for contamination and the need for strict quality control measures.
Bioprocessing: FACS technology can be used in bioprocessing applications, such as the production of monoclonal antibodies or other biologics. The market potential for this application of FACS technology is large, but the risks associated with it include the high cost of implementation and the need for specialized expertise.
Environmental monitoring: FACS technology can be used for environmental monitoring, such as the detection and quantification of microorganisms in water or soil samples. The market potential for this application of FACS technology is moderate, but the risks associated with it include the potential for false positives or negatives due to the complexity of environmental samples.
Overall, the future use cases of FACS technology are broad and varied, with potential for high market potential in multiple industries. However, the adoption of FACS technology in these applications may be limited by various factors, including cost, complexity, and the need for specialized expertise. The risks associated with FACS technology also vary depending on the specific application, but can include issues related to contamination, quality control, and accuracy of results. As with any new technology, careful consideration of these factors will be essential in determining the success and potential impact of FACS technology in the future.
Growth opportunities and latent adjacency in Flow Cytometry Market
What are the growth opportunities in the North American region for the global flow cytometry market?
How much share, does the each segment holds, of the global Flow Cytometry Market?
How the end user segment is benefited by the emerging innovations in the Global Flow Cytometry Market?
How the North American region is expected to dominate the Global Flow Cytometry Market?